Mirabegron for treatment of erectile dysfunction concomitant with lower urinary tract symptoms in patients with benign prostatic obstruction: A randomized controlled trial

To assess the efficacy of mirabegron in the treatment of erectile dysfunction concomitant with lower urinary tract symptoms in benign prostatic obstruction patients.

[1]  T. Zeng,et al.  Efficacy and Side Effects of Drugs Commonly Used for the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia , 2020, Frontiers in Pharmacology.

[2]  C. Roehrborn,et al.  Model‐based meta‐analysis of individual International Prostate Symptom Score trajectories in patients with benign prostatic hyperplasia with moderate or severe symptoms , 2020, British journal of clinical pharmacology.

[3]  S. Kaplan,et al.  Efficacy and Safety of Mirabegron versus Placebo Add-On Therapy in Men with Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Randomized, Phase 4 Study (PLUS). , 2020, The Journal of urology.

[4]  Zhipeng Chen,et al.  The efficacy and safety of mirabegron on overactive bladder induced by benign prostatic hyperplasia in men receiving tamsulosin therapy , 2020, Medicine.

[5]  Wei-Chia Lee,et al.  Effect of mirabegron on erectile function in sexually active men with bothersome overactive bladder symptoms , 2019, Journal of the Chinese Medical Association : JCMA.

[6]  P. Cuijpers,et al.  The International Index of Erectile Function (IIEF)-A Systematic Review of Measurement Properties. , 2019, The journal of sexual medicine.

[7]  C. Mamoulakis,et al.  The effect of mirabegron, used for overactive bladder treatment, on female sexual function: a prospective controlled study , 2018, BMC Urology.

[8]  G. Tirabassi,et al.  Sexual dysfunction in subjects treated with inhibitors of 5α‐reductase for benign prostatic hyperplasia: a comprehensive review and meta‐analysis , 2017, Andrology.

[9]  N. Sofikitis,et al.  PS-07-005 The impact of mirabegron on erectile function of males with overactive bladder , 2017 .

[10]  H. Kakizaki,et al.  Urodynamic Efficacy and Safety of Mirabegron Add‐on Treatment with Tamsulosin for Japanese Male Patients with Overactive Bladder , 2016, Lower urinary tract symptoms.

[11]  W. Hellstrom,et al.  Mirabegron causes relaxation of human and rat corpus cavernosum: could it be a potential therapy for erectile dysfunction? , 2016, BJU international.

[12]  C. Roehrborn,et al.  Erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) combined responders to tadalafil after 12 weeks of treatment , 2016, BJU international.

[13]  Nan Li,et al.  The efficacy of PDE5 inhibitors alone or in combination with alpha-blockers for the treatment of erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and meta-analysis. , 2014, The journal of sexual medicine.

[14]  S. Kaplan,et al.  Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder. , 2013, European urology.

[15]  G. Amarenco,et al.  Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. , 2013, European urology.

[16]  M. Elhilali,et al.  Male sexual function outcome after three laser prostate surgical techniques: a single center perspective. , 2012, Urology.

[17]  D. Cox,et al.  Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. , 2012, European urology.

[18]  K. Coyne,et al.  Overactive bladder is associated with erectile dysfunction and reduced sexual quality of life in men. , 2008, The journal of sexual medicine.

[19]  C. Roehrborn,et al.  Prostatic Diseases and Male Voiding Dysfunction Effects of Serum PSA on Efficacy of Tolterodine Extended Release With or Without Tamsulosin in Men With LUTS, Including OAB , 2008 .

[20]  I. Goldstein,et al.  ORIGINAL RESEARCH—OUTCOMES ASSESSMENT: Validation of the Erection Hardness Score , 2007 .

[21]  G. Bartsch,et al.  Atherosclerosis as a risk factor for benign prostatic hyperplasia , 2006, BJU international.

[22]  T. Lue,et al.  Phosphodiesterase type 5 inhibitors for erectile dysfunction , 2005, BJU international.

[23]  R. Rosen,et al.  Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). , 2005, European urology.

[24]  B. Trock,et al.  Clinical efficacy of sildenafil citrate and predictors of long-term response. , 2003, The Journal of urology.

[25]  L. Ignarro,et al.  Involvement of β3-adrenergic receptor activation via cyclic GMP- but not NO-dependent mechanisms in human corpus cavernosum function , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[26]  H. Lepor,et al.  Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia. , 2001, Urology.

[27]  R. Moore,et al.  Benign prostatic hyperplasia (the aging prostate). , 1999, The Medical clinics of North America.

[28]  Yuanshan Cui,et al.  The efficacy and safety of mirabegron in treating OAB: a systematic review and meta-analysis of phase III trials , 2013, International Urology and Nephrology.

[29]  I. Goldstein,et al.  Validation of the erection hardness score. , 2007, The journal of sexual medicine.